Drug Profile
Research programme: cancer therapeutics - Oncoceutics
Alternative Names: Imipridone compounds - Oncoceutics; ONC 213; ONC 222; ONC 235; ONC 400; ONC202Latest Information Update: 28 Nov 2023
Price :
$50
*
At a glance
- Originator Oncoceutics
- Developer Brown University; Oncoceutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Dopamine D2 receptor antagonists; Extracellular signal-regulated MAP kinase inhibitors; G protein-coupled receptor agonists; Proto oncogene protein c-akt inhibitors; Ras signal transduction pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Haematological malignancies; Pancreatic cancer; Solid tumours
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for preclinical development in Pancreatic-cancer in USA
- 28 Aug 2023 No recent reports of development identified for preclinical development in Haematological-malignancies in USA
- 28 Aug 2023 No recent reports of development identified for preclinical development in Solid-tumours in USA